8-KLeadership Changes

STRYKER CORP 8-K Report, Executive Changes (Jul 10, 2018)

Filed July 10, 2018For Securities:SYK

Summary

Stryker Corporation (SYK) has announced a significant leadership transition. David K. Floyd, Group President of Orthopaedics, will retire from his role effective August 1, 2018. To ensure a smooth handover, Mr. Floyd will remain with the company as an advisor to the CEO and continue in his Group President role until June 30, 2019, receiving his current salary and bonus eligibility. Concurrently, Timothy J. Scannell, currently Group President of MedSurg and Neurotechnology, will be promoted to President and Chief Operating Officer, also effective August 1, 2018. Mr. Scannell, who has a long tenure with Stryker, will receive a base salary of $750,000, with a 100% bonus potential. His appointment also includes a substantial equity package, comprising restricted stock units, stock options, and performance stock units, reflecting the company's investment in his leadership for future growth.

Key Highlights

  • 1David K. Floyd is retiring as Group President, Orthopaedics, effective August 1, 2018.
  • 2Floyd will transition to an advisory role until June 30, 2019, to ensure a smooth transition.
  • 3Timothy J. Scannell is appointed President and Chief Operating Officer, effective August 1, 2018.
  • 4Scannell's new compensation includes a $750,000 base salary and 100% bonus potential.
  • 5Scannell will receive approximately $1.9 million in restricted stock units upon appointment, vesting over three years.
  • 6Scannell is also slated to receive approximately $5 million in stock options and performance stock units in February 2019.
  • 7This filing also lists the Letter Agreement with David K. Floyd as an exhibit.

Frequently Asked Questions

David K. Floyd's retirement from his role as Group President, Orthopaedics is being managed through a transition plan. He will continue to serve in an advisory capacity to the CEO and retain his Group President title until June 30, 2019, ensuring continuity and knowledge transfer. This approach aims to minimize disruption to the Orthopaedics division.

Timothy J. Scannell's appointment to President and Chief Operating Officer signifies a broadening of his executive responsibilities. He was previously Group President, MedSurg and Neurotechnology, and his new role suggests oversight of a larger operational scope within Stryker, likely encompassing strategy execution and day-to-day management across key business segments.

Mr. Scannell's compensation package includes a $750,000 base salary, a 100% annual bonus potential, and significant equity awards. The restricted stock units, stock options, and performance stock units, valued at approximately $6.9 million in total, demonstrate Stryker's commitment to retaining and incentivizing key leadership for long-term performance and shareholder value creation.

This 8-K filing specifically focuses on the retirement of David K. Floyd and the appointment and compensation of Timothy J. Scannell to the role of President and Chief Operating Officer. No other senior officer departures or appointments are detailed in this specific report.